

Proven History of Safe and Effective Units for Transplant

Transplants for Hematopoietic Diseases										
Disease Treated	Chemo/Radiation Required	Facility	Date of Use	Donor Relationship	Recipient Age (yrs) (x 4.5)	Time Stored (months)	Engraftment Time	Cord Volume Collected (mL)	Nucleated Cell Count (x10 ⁶)	Total CD34+ Cells (x10 ⁶)
Acute Lymphoblastic Leukemia	Y	University of Miami	6/20/96	Sibling	7	3	45 Days	64	7.4	2.4
Wiscott Aldrich Syndrome	Y	Fred Hutchinson Cancer Research Center	11/14/97	Sibling	3	4	30 Days	158	14.2	9.5
Acute Myelogenous Leukemia	Y	Rush University Medical Center	12/24/97	Sibling	3	<1	13 Days	59	7.1	1.1
Fanconi Anemia	Y	Johns Hopkins	6/15/99	Sibling	4	8	17 Days	113	15.1	16
Sickle Cell Anemia	Y	St. Judes Children's Research Hospital	2/2/00	Sibling	8	24	24 Days	105	10.6	2.3
Thalassemia Major	Y	Miami Children's Hospital	12/14/00	Sibling	4	23	45 Days	46	6.2	0.37
Severe Aplastic Anemia	Y	Mount Sinai Hospital	4/2/01	Autologous (Self)	2	20	10 Days	102	14.1	4.9
Severe Aplastic Anemia	Y	Memorial Sloan-Kettering Cancer Center	6/27/01	Sibling	10	36	13 Days	87	10.8	5.4
Neuroblastoma	Y	The Children's Hospital	12/11/01	Autologous (Self)	6	69	57 Days	51	4.1	0.25
Fanconi Anemia	Y	Fairview University Medical Center	4/23/02	Sibling	3	16	24 Days	14	1.1	0.01
Fanconi Anemia	Y	Cincinnati Children's Hospital	8/29/03	Sibling	5	80	N/A ¹	67	6.9	2.9
Sickle Cell Anemia	Y	Columbia-Presbyterian Medical Center	1/22/04	Sibling	3	6	33 Days	45	3.04	1.15
Fanconi Anemia	Y	Cincinnati Children's Hospital	1/27/05	Sibling	9	6	27 Days	53	3.15	1
Acute Myelogenous Leukemia	Y	University Medical Center, Tuscon AZ	3/22/05	Sibling	4	28	18 Days	80	6.86	5.83
Sickle Cell Anemia	Y	University of Mississippi Medical Center	9/28/05	Sibling	10	12	17 Days	50	3.42	0.56
Adrenoleukodystrophy	Y	Duke University Medical Center	10/13/05	Sibling	0.5	38	10 Days	60	6.96	2.62
Severe Aplastic Anemia	Y	New York Medical Center	12/23/05	Sibling	6.5	10	18 Days	48	7.7	10
Acute Myelogenous Leukemia	Y	UCLA	10/20/06	Sibling	4	<1	19 Days	79	7.7	3.33
Acute Myelogenous Leukemia	Y	Riley Hospital for Children	12/8/06	Sibling	3.25	2	27 Days	83	6.58	1.95
Sickle Cell Anemia	Y	Mount Sinai Hospital	1/18/07	Sibling	6	21	12 Days	127	7.77	3.03
Acute Myelogenous Leukemia	Y	Columbus Children's Hospital	1/25/07	Sibling	7	38	17 Days	66	2.77	1.3
Acute Lymphoblastic Leukemia	Y	University of North Carolina's Medical Center	5/16/07	Sibling	6.5	39	Pending*	116	16.54	7.06
Severe Combined Immune Deficiency	Y	Cincinnati Children's Hospital	6/4/07	Sibling	6	5	Pending*	73	6.7	1.7
Severe Aplastic Anemia	Y	Children's Hospital of Wisconsin	6/8/07	Sibling	4	3	Pending*	106	15.22	3.52

Transplants for Non-Hematopoietic Diseases										
Disease Treated	Chemo/Radiation Required	Facility	Date of Use	Donor Relationship	Recipient Age (yrs) (x 4.5)	Time Stored (months)	Engraftment Time	Cord Volume Collected (mL)	Nucleated Cell Count (x10 ⁶)	Total CD34+ Cells (x10 ⁶)
Chronic Granulomatous Disease	Y	Hackensack University Medical Center	4/25/02	Sibling	6	11	N/A ²	63	7.2	0.86
Ectodermal Dysplasia	Y	Dana Farber	10/29/04	Sibling	5	7	14 Days	66	9.65	1.33
Severe Congenital Neutropenia	Y	Schneider's Children's Hospital	2/8/07	Sibling	3	29	18 Days	41	3.08	0.92
Brain Cancer	Y	Shands Transplant Center	3/29/07	Autologous (Self)	11 mos.	11	Pending*	23	2.65	0.68

Increasing the Potential Uses of Cord Blood

Infusions – Emerging Treatments										
Disease Treated**	Chemo/Radiation Required	Facility	Date of Use	Donor Relationship	Recipient Age (yrs) (x 4.5)	Time Stored (months)	Engraftment Time	Cord Volume Collected (mL)	Nucleated Cell Count (>10 ⁶)	Total CD34+ Cells (>10 ⁶)
Disgenesis of the corpus callosum	N	Duke University Medical Center	3/20/07	Autologous (Self)	1.5	17	N/A	98	13.97	6.26
Type I Diabetes	N	Miami Children's Hospital	3/23/07	Autologous (Self)	10	126	N/A	48	6.1	3.9

¹ Engraftment occurred with a follow up bone marrow transplant 28 days later from the same sibling.

² Engraftment occurred with a follow up stem cell transplant using bone marrow from the same sibling. The patient experienced autologous hematopoietic recovery.

*Transplant results are not reported until at least post 100 days after transplant date.

**Cord blood stem cell research to treat these additional diseases is experimental. These diseases are not on the list of diseases currently considered to be treated with cord blood stem cells and may never be considered to be diseases that can be effectively treated with cord blood stem cells. The odds are relatively low that cord blood you elect to store will be used to treat a family member.

ViaCord and CHORI Announce 100th Cord Blood Transplant.

Represents Most Related Cord Blood Transplant Experience

These 100 cord blood units include transplant units released through ViaCord (see other side) and units stored through Children’s Hospital Oakland Research Institute’s (CHORI) Sibling Donor Cord Blood Program. This program provides ViaCord’s comprehensive cord blood collection, processing, and five years of storage at no cost to families who have a child in need of a transplant for a disease currently treated with cord blood.

“After thorough due diligence in assessing the field, I am confident that ViaCord processes cells in a high quality manner suitable for transplant.”

– Dr. Bertram H. Lubin, Director of Medical Research at CHORI

How To Measure Transplant Success

The 3 widely accepted measurements of transplant success are: Survival, GvHD and Engraftment.

Transplant Outcomes Data

	ViaCord + CHORI Transplants – Related* (median)	Published Data – Unrelated* (median)
1-Year Survival Rate	82% (n=83) ¹	61% (n=1623)
Acute GvHD Rate	25% (n=91) ²	43% (n=1623)
Neutrophil Engraft Rate	94% (n=91) ²	83% (n=1623)

*All transplants based on data compiled 06-07. Data on file.

¹Number of transplants reflects transplants occurring more than one year ago (06-06).

²Transplant results are not reported until at least 100 days post transplant date.

The ViaCord Advantage

- ▶ **ViaCord is the ONLY Family Cord Blood Banking Company that publishes Transplant Outcome Data**
- ▶ **ViaCord + CHORI’s combined transplants represent the most related cord blood transplant experience**
- ▶ **ViaCord offers transplant physicians confidence that cells are stored in a high quality manner**

VIACORD

Cord Blood Banking
+ Research™



ViaCord’s Cord Blood Donor Program